NOMAD POWER SOLUTIONS, INC.
NMAD evidence brief
What we can confirm
- BioSniper Score:
- 5.7 / 10
- Market Cap:
- $58.0M
- Lead Asset:
- lb-100 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for NMAD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NMAD
NOMAD POWER SOLUTIONS, INC. (NMAD) is a clinical-stage biopharmaceutical company developing PP2A inhibitor LB-100 for cancer therapy and the LiGHT proton therapy system, with no revenue and substantial going-concern risk.
Key risk: Going concern risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$58.0M
Cash Runway
—
Lead Asset
lb-100 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for NOMAD POWER SOLUTIONS, INC..
NOMAD POWER SOLUTIONS, INC. (NMAD) is a clinical-stage biopharmaceutical company developing PP2A inhibitor LB-100 for cancer therapy and the LiGHT proton therapy system, with no revenue and substantial going-concern risk.
- Clinical-stage biopharmaceutical company focused on PP2A inhibitors for cancer treatment [sec_mda · as of 2026-08-14].
- Lead product candidate is LB-100, a PP2A inhibitor in clinical development [sec_mda · as of 2026-08-14].
- Also developing the LiGHT System (Linac for Image Guided Hadron Therapy) for proton therapy [sec_mda · as of 2026-03-31].
- Shareholders' equity of $23.9M as of 2026-06-30 [sec].
- Cash of $3,250,650 as of March 31, 2026, with a net loss of $1,987,608 for the three months ended March 31, 2026 [sec_mda · as of 2026-05-14].
What works
- LB-100 has shown clinical anti-cancer activity and is being evaluated in multiple clinical trials [sec_mda · as of 2026-08-14].
- The Company holds a proprietary technology (LiGHT System) with advantages over current proton therapy technologies [sec_mda · as of 2026-03-31].
- The Company operates with limited overhead to advance development programs efficiently [sec_mda · as of 2026-08-14].
What to weigh
- The Company has not generated revenue or positive cash flows from operations and relies on external financing [sec_mda · as of 2026-08-14].
- There is substantial doubt about the Company's ability to continue as a going concern for at least 12 months beyond the filing of its quarterly report [sec_mda · as of 2026-05-14].
- The Company expects it will need to raise additional capital as development milestones are achieved, with no assurance of securing such capital [sec_mda · as of 2026-08-14].
- Clinical trials could be placed on hold due to serious adverse events [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
LB-100 is the principal product candidate, a PP2A inhibitor in clinical development.
“The Company's principal product candidate is LB-100, a PP2A inhibitor currently undergoing clinical development.”
SEC MD&A · August 14, 2026
The Company has not generated revenue and relies on financing.
“The Company has not commenced revenue-generating operations, has not generated positive cash flows from operations and relies, in part, on stock-based compensation to compensate employees and consultants.”
SEC MD&A · August 14, 2026
Going concern risk is substantial.
“management has concluded that there is a substantial doubt regarding the Company's ability to continue as a going concern for a period of at least 12 months beyond the filing of this quarterly report.”
SEC MD&A · May 14, 2026
Cash position and net loss as of March 31, 2026.
“For the three months ended March 31, 2026, the Company incurred a net loss of $1,987,608 and used cash in operations of $1,831,363. As of March 31, 2026, the Company had cash of $3,250,650 available to fund its operations.”
SEC MD&A · May 14, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Substantial doubt about ability to continue as a going concern for at least 12 months [sec_mda · as of 2026-05-14].
- No revenue generation — Company has not generated revenue or positive cash flows since inception [sec_mda · as of 2026-08-14].
- Dependence on financing — Needs additional capital to fund operations and development; no assurance of obtaining it [sec_mda · as of 2026-08-14].
- Clinical trial risks — Trials could be placed on hold due to serious adverse events [sec_mda · as of 2026-08-14].
What to watch
- Completion of the Phase 1b/randomized Phase 2 study of LB-100 plus doxorubicin for ASTS, expected report by December 31, 2026 [sec_mda · as of 2026-03-31].
- Ability to raise additional capital to fund operations and development milestones [sec_mda · as of 2026-08-14].
- Potential strategic collaborations or licensing agreements with pharmaceutical companies [sec_mda · as of 2026-08-14].
- Cash runway and burn rate given cash of $3.25M as of March 31, 2026 [sec_mda · as of 2026-05-14].
Sources: SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run NOMAD POWER SOLUTIONS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NOMAD POWER SOLUTIONS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.07 · 0% dilution
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of May 21, 2026- % of float
- 0.2%
- Days to cover
- 0.7
- Shares short
- 24,410
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NMAD short interestGovernance
Frequently asked questions
What is the AI investment thesis for NOMAD POWER SOLUTIONS, INC.?
NOMAD POWER SOLUTIONS, INC. (NMAD) is a clinical-stage biopharmaceutical company developing PP2A inhibitor LB-100 for cancer therapy and the LiGHT proton therapy system, with no revenue and substantial going-concern risk.
What is NOMAD POWER SOLUTIONS, INC.'s lead drug candidate?
NOMAD POWER SOLUTIONS, INC.'s most advanced tracked candidate is lb-100 (Phase 1) for Advanced Soft Tissue Sarcoma.
Who is the CEO of NOMAD POWER SOLUTIONS, INC.?
Mr. Geordan G. Pursglove is the chief executive officer of NOMAD POWER SOLUTIONS, INC. (NMAD).
Where is NOMAD POWER SOLUTIONS, INC. headquartered?
NOMAD POWER SOLUTIONS, INC. (NMAD) is headquartered in Boca Raton, FL, United States.
What therapeutic areas does NOMAD POWER SOLUTIONS, INC. focus on?
NOMAD POWER SOLUTIONS, INC. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.